CJC-1295 + Ipamorelin 10mg – GH Secretagogue Research Blend

← Back to WP3 Peptides & Research Index

What the CJC-1295 + Ipamorelin blend is

This blend co-formulates a long-acting growth hormone–releasing hormone (GHRH) analog with a selective growth hormone secretagogue receptor (GHS-R1a) agonist. CJC-1295 is a 30-amino-acid GHRH(1–29) analog with stabilizing residue substitutions; the non-DAC variant has a half-life of approximately 30 minutes, while the DAC-modified variant is albumin-conjugated for extended exposure (Teichman et al., 2006 — PMID 16352683). Ipamorelin is a synthetic pentapeptide selective for GHS-R1a, the endogenous ghrelin receptor, with minimal cross-reactivity at receptors governing prolactin, cortisol, or ACTH release (Raun et al., 1998 — PMID 9849822). The two peptides are studied together because GHRH and ghrelin-axis signaling converge on pituitary somatotrophs through complementary pathways.

Mechanism of action

CJC-1295 binds the GHRH receptor on anterior pituitary somatotrophs, a class B GPCR coupled to Gαs, increasing cAMP and PKA-dependent CREB phosphorylation that drives GH gene transcription and granule exocytosis. Ipamorelin engages GHS-R1a, a class A GPCR coupled to Gαq/11, activating phospholipase C and mobilizing intracellular calcium via IP₃-mediated release. When somatotrophs receive both inputs simultaneously, the cAMP-driven priming from GHRH potentiates the calcium-driven exocytotic response from GHS-R1a, producing greater GH release than either signal alone. This synergistic phenomenon has been demonstrated in pituitary perfusion systems and in human pharmacology studies of combined GHRH and GHRP administration. Importantly, GH pulsatility is preserved because pulses are governed by hypothalamic somatostatin tone rather than by GHRH input alone (Teichman et al., 2006 — PMID 16352683).

Historical & structural context

The combination of GHRH and ghrelin-receptor agonists for amplified GH release has a long pre-clinical and clinical history. As early as the late 1980s and 1990s, co-administration of GHRH with the GHRP-6 hexapeptide was shown to produce GH release substantially greater than either alone in human pharmacology studies. Subsequent work with later-generation GHS-R agonists (hexarelin, ipamorelin) confirmed that the synergy reflects the convergent intracellular signaling of cAMP-driven priming and calcium-driven exocytosis on a single somatotroph cell. CJC-1295 + ipamorelin co-formulation extends this concept by pairing a long-acting GHRH analog with a selective GHS-R agonist, allowing investigators to study sustained dual-input pharmacology.

Methodological considerations

For combination work, investigators should (1) characterize each peptide's individual pharmacodynamics in the chosen system before combining, since combined readouts otherwise confound mechanism; (2) account for receptor desensitization timescales differing between GHRHR and GHS-R1a, with the latter typically showing more rapid tachyphylaxis under repeated dosing; (3) sample IGF-1 on a schedule appropriate for the longer-half-life component (the DAC variant of CJC-1295); (4) include appropriate single-agent and vehicle controls — combination synergy is convincingly demonstrated only when both monotherapy arms are present; (5) consider somatostatin tone, which differs between fed and fasted states and can substantially alter the magnitude of synergy observed.

Research applications

The blend is investigated as a tool combination for:

• Mechanistic studies of GHRH-ghrelin axis synergy at the pituitary level (Smith, 2005 — PMID 15814848).
• Pharmacodynamic profiling of pulsatile GH release under sustained dual input.
• IGF-1 axis dynamics and downstream hepatic IGF-1 production studies.
• Comparative pharmacology against single-agent GHRH analogs and GHS-R agonists.
• Receptor-desensitization and tachyphylaxis investigations under chronic dosing schedules.

Stability & handling notes

Lyophilized blend material is typically stable at −20 °C for 24 months. After reconstitution in sterile or bacteriostatic water, working aliquots are stored at 2–8 °C and used within approximately 14 days, with bulk reconstituted material at −20 °C. Co-formulation does not change the inherent stability of either component; investigators evaluating mechanism should still characterize each peptide individually before relying on combined readouts.

Common research dosing reference

Published rodent and human pharmacology studies have used CJC-1295 (DAC) at 30–250 μg/kg subcutaneously and ipamorelin at 1–90 μg/kg in acute pharmacodynamic protocols. These values are research benchmarks only and have no implication for clinical or therapeutic dosing.

Quality & specifications

Reference-grade material is typically characterized by reverse-phase HPLC purity ≥98%, electrospray-ionization mass spectrometry (ESI-MS) confirming the expected monoisotopic mass, and quantitative amino-acid analysis where applicable. Cell-culture-grade lots additionally include endotoxin testing by Limulus amebocyte lysate (LAL) assay and bioburden screening. Each lot is shipped with a Certificate of Analysis itemizing purity, identity, residual solvents, water content (Karl Fischer), and acetate or trifluoroacetate counter-ion content where relevant. Investigators evaluating new lots should request raw chromatograms and mass spectra prior to incorporation into published work.

Pharmacology in context

The combination of GHRH analog with GHS-R agonist sits in a long lineage of dual-agonist GH-axis research that began with GHRH+GHRP-6 protocols in the late 1980s and continued with GHRH+hexarelin and GHRH+ipamorelin combinations through the 2000s. Across this literature, the consistent finding has been that combined administration produces GH release exceeding the sum of individual contributions, implicating mechanistic synergy rather than simple additivity. The specific CJC-1295 + ipamorelin pairing extends this concept by combining a long-acting GHRH analog with a selective GHS-R1a agonist, allowing dual-input pharmacology to be studied across longer timescales than were possible with short-acting GHRPs.

Reporting & reproducibility expectations

Publications using the blend should report: (a) supplier, lot, HPLC purity, and mass-spec verification for each component, with explicit confirmation that the formulation is a true co-formulation rather than sequential single-agent dosing; (b) DAC vs non-DAC status of the CJC-1295 component; (c) reconstitution buffer and storage history; (d) for synergy claims, full single-agent control arms at matched doses; (e) sampling schedule appropriate to the longer-half-life component; (f) baseline GH, IGF-1, cortisol, and prolactin values to support specificity claims. Single-arm or under-controlled studies cannot support synergy conclusions and should be interpreted accordingly.

Compliance & regulatory framing

This material is provided strictly for research and educational reference. The compound is supplied for in vitro investigation and laboratory characterization only and is not intended for human ingestion, injection, topical use, or any clinical application. Federal and state law treats research peptides as non-therapeutic chemicals; recipients are responsible for compliance with all applicable institutional, state, and federal regulations governing handling, storage, and disposal. Pricing, availability, and supply specifications are subject to change without notice. Request a Certificate of Analysis (COA), HPLC chromatograms, mass-spec verification, or compliance documentation from the Clinical Advisory Team for any specific lot.

Related research compounds

The component peptides are documented separately at CJC-1295 and Ipamorelin. Investigators studying the GH/IGF-1 axis may also reference Tesamorelin 15 mg.

Sourcing & analytical verification

For blend formulations, investigators should request HPLC chromatograms documenting the resolution of both peptides, mass-spec verification of each component, and explicit documentation of the molar or mass ratio between CJC-1295 and ipamorelin in the supplied lot. Some commercial preparations are 1:1 by mass (yielding very different molar ratios given the substantial molecular-weight difference between the two peptides), while others are formulated to specific molar ratios; protocols must specify and verify which is in use. Endotoxin testing is required for cell-culture work in pituitary lines. Orthogonal pharmacodynamic verification — for instance, GH release from cultured somatotrophs — provides additional confidence in lot bioactivity beyond chemical characterization.

References

References below are anchor PubMed citations. Readers are encouraged to verify each in the National Library of Medicine database before using as a research source.

1. Teichman SL, et al. Prolonged GH and IGF-I secretion by CJC-1295. JCEM, 2006. PMID 16352683.
2. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998. PMID 9849822.
3. Smith RG. Development of growth hormone secretagogues. Endocrine Reviews, 2005. PMID 15814848.
4. Jetté L, et al. hGRF(1-29)-albumin bioconjugates. Endocrinology, 2005. PMID 15817669.
5. Frohman LA, Jansson JO. Growth hormone-releasing hormone. Endocrine Reviews, 1986. PMID 2874984.
6. Johansen PB, et al. Ipamorelin pharmacokinetics in animal models. Growth Hormone & IGF Research, 1999.

For Research Use Only. Not for human or veterinary consumption, diagnostic procedures, or therapeutic use. Content is educational and non-promotional.